LEN vs SERA · rev $34.19B vs rev $77.0K
LEN (LEN) versus Sera Prognostics Inc (SERA) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Sera Prognostics Inc (SERA) is a medical devices company listed on US.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported SERA revenue for 2024-12-31 was $77.0K. Net income was -$32.9M. Revenue was down 74.8% from 2023-12-31 to 2024-12-31. SERA currently screens at market cap $89.1M.
LEN currently screens at market cap $0. SERA currently screens at market cap $89.1M.
Not investment advice. Open the LEN and SERA stock pages for the full models.
Not investment advice.